Hepatitis surface antigen particle vaccine
CA 1341021 C · Owner: Novartis Vaccines And Diagnostics, Inc. · Inventors: Valenzuela, Pablo D. T.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Vaccines are provided produced by hybrid DNA technology for Hepatitis B virus comprising Hepatitis B 5 surface antigen particles containing a human polyalbumin binding site receptor. Constructs are provided for expression of the vaccine protein, which upon transformation, in an appropriate host results in the production of particles useful as vaccines. The yeast strain S. carlsbergensis strain 2150-2-3 (pHBpreS-347/33T) was deposited at the A.T.C.C. on 14 June 1984 and given Accession No. 20716.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Granted June 13, 2000. A Canadian patent filed before October 1, 1989 lasted 17 years from grant, so its term ended June 13, 2017.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.